Pharmaceuticals, Biotechnology and Life Sciences
Diplomat Pharmacy will distribute Novartis’s newly approved breast cancer drug Kisqali (ribociclib) as a first-line treatment for postmenopausal women with a serious form of the disease.
In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020.
The U.S. Patent and Trademark Office (USPTO) has been favorable to Ceylad for the fourth time for production of Allogenic TCR-Deficient CAR-T cells.
Millennium Dental Technologies, Inc. has reached milestone today in the one-year anniversary of the world’s first and only US FDA clearance for full-mouth True Periodontal Regeneration.
Decision Resources Group (DRG) finds that Nucala’s novel mechanism of action and specific indication for eosinophilic asthma are key drivers behind the agent’s recent success in the severe asthma market.
Sweden-based pharmaceutical development company focusing on immunological diseases InDex Pharmaceuticals Holding AB has been granted a patent covering 19 compounds from the company’s DIMS platform by the United States Patent and Trademark Office (USPTO).
Ahead of Tuesday’s trading session, Stock-Callers.com puts focus on four major players in the Drug Manufacturers space.
AMO Pharma Limited and Ranedis Pharmaceuticals,two privately held U.S. pharma companies have partnered up to develop RND-001 for rare genetic diseases, including certain lysosomal storage disorders and other diseases affecting the central nervous system.
The expansion of product lines and enhanced product development are fueling rising revenues and overall growth in the swelling cannabis market despite recent ambiguous reports of direction of the federal impact on the legal marijuana market
The US Food and Drug Administration (FDA) has approved Novartis’s Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.